Extended Data Fig. 12: In vitro and in vivo sensitivity of Fgfr2 variants to FGFRi.
From: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
a, Dose-response curves of 2D-grown NMuMG cells expressing GFP or indicated Fgfr2 variants and treated with AZD4547, pemigatinib, BGJ398, or debio-1347 for 4 days. Data are represented as mean ± s.d. of n = 5 replica per group collected across 5 independent experiments. b, Half-maximum inhibitory concentration (IC50) value quantifications of BGJ398 and debio-1347 dose-response curves in a. Data are represented as mean of 3 independent experiments (GFP, Fgfr2FL, Fgfr2ΔE18) or 1 experiment (other Fgfr2 variants). IC50 values for AZD4547 and pemigatinib are displayed in Fig. 4a. c, Individual growth curves of indicated tumour donors transplanted into the mammary fat pad of female syngeneic WT mice and treated daily orally with vehicle or 12.5 mg/kg AZD4547 using a previously established55 intermittent dosing regimen. d, Selected tumour transplant growth curves of mice in c. Durations of AZD4547 treatments according to intermittent dosing regimen are indicated.
